In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Life Sciences 4.0: Securing Value Through Data-Driven Platforms

How companies can participate in new platforms of care?

Laying the foundation

At least initially, multiple care platforms for the same disease area or health purpose will be created. Over time, leading platforms in specific disease categories will emerge as users gravitate to platforms that provide greater value. As organizations build data and analytics capabilities, supra-platform aggregators will connect data generated from discrete disease-specific platforms to help individuals and health systems address larger health goals.

Multiple stakeholders across multiple industries will contribute resources to create functional platforms of care. Collaborations must span public and private entities and include organizations from health care, consumer products, technology and life sciences.

Creating tomorrow’s care platforms

To better understand where companies are partnering to build capabilities or access resources, EY interviewed more than 25 life sciences leaders and analyzed more than 150 digitally focused partnerships announced between life sciences companies and other stakeholders since 2014.

No single external database tracks partnerships of a digital nature, so EY created its own digital deals database, searching company reports, news releases and third-party analyst reports for relevant partnerships. Our study reveals a complicated web of relationships emerging between biopharma, medtech, digital health start-ups and technology companies.

EY also analyzed the findings to understand the growth in partnerships over time, the therapeutic areas commanding the greatest interest and the types of capabilities being accessed. Of the nearly 90 partnerships with a clear therapeutic area of focus, 50% of them involve platform capabilities in the diabetes or respiratory arenas, while 14% involve oncology-focused products or services.

EY.Deals-Asset_1807_790.gif

Source: EY research. Based on sample of non-exhaustive data from 2014 -2017. © 2018 EYGM Limited. All Rights Reserved. ED None.

The importance of being brand-agnostic

Currently, product developers interested in accelerating customer-centric care platforms will consolidate capabilities in given disease areas to further extend market reach and know-how. As product developers join forces with innovators, payers and physicians to develop more integrated solutions, emphasis will shift to the creation of more holistic care platforms that manage complicated disease conditions across the care continuum.

To be most successful, these holistic platforms shouldn’t be designed to drive sales of certain therapeutics or devices. There are regulatory, ethical and practical reasons why life sciences companies must embrace brand-agnostic platforms that address wider issues related to the customer’s day-to-day experience with his or her disease.

Click here to keep reading and download the complete report.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

IV005365

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel